Observational Safety Data Analysis From Routine Follow-up in the EuroSIDA Study of Patients Treated With Raltegravir in a Five-Year Post Authorization Period
Latest Information Update: 11 May 2022
At a glance
- Drugs Raltegravir (Primary) ; Antiretrovirals
- Indications HIV-1 infections
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme Corp.
Most Recent Events
- 03 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 06 Mar 2010 New trial record